On October 2, 2023, the Board of Directors of FibroGen, Inc. appointed Interim Chief Executive Officer Thane Wettig as a member of the Board. Mr. Wettig was appointed as a Class I director for the term expiring at the Company?s 2024 annual meeting of stockholders. Mr. Wettig held the position of Interim Chief Executive Officer since July 23, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.22 USD | +7.96% | +7.96% | +37.65% |
05-07 | Top Premarket Gainers | MT |
05-06 | Transcript : FibroGen, Inc., Q1 2024 Earnings Call, May 06, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.65% | 121M | |
+23.37% | 47.02B | |
+49.79% | 41.86B | |
-0.94% | 41.76B | |
-5.86% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- FGEN Stock
- News FibroGen, Inc.
- FibroGen, Inc. Appoints Thane Wettig as a Member of the Board